Medicine pack check sheet

Source-linked reading points

• Check MOBIC, meloxicam, oral-tablet form, actual strength and target market together. The 7.5 and 15 mg figures are historical labelled amounts per tablet, not how many tablets anyone should use, and they cannot self-convert another anti-inflammatory pain medicine, form or market product.
• The label flags that MOBIC should not be self-combined with other NSAIDs or salicylate products because such combinations require professional assessment. If aspirin, ibuprofen, celecoxib, cold/pain products, anticoagulants, herbs or supplements are also present, have a pharmacist or prescriber review every actual pack and the full medicine list rather than deciding from the word “pain.”
• The FDA label carries boxed warnings about serious cardiovascular and gastrointestinal risks and notes a higher risk of serious gastrointestinal events in older people. These warnings cannot become an individual stop-or-switch instruction on a webpage; chest pain, shortness of breath, unusual weakness, slurred speech, vomiting blood, black stools or another acute serious concern require local urgent medical care.
• The historical label also identifies kidney and liver context, prior ulcer or bleeding, cardiovascular context and multiple medicines as situations needing professional review. It does not replace the current leaflet for the exact product in hand; for splitting, missed use, adjustment or switching, first have a pharmacist or prescribing team review the actual pack and full medicine list.